Centessa Pharmaceuticals

Update in progress

CNTA (NGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Centessa Pharmaceuticals is a clinical-stage company that discovers, develops, and delivers medicines. Its lead program, ORX750, is an orally delivered OX2R agonist in Phase 2a for idiopathic hypersomnia and narcolepsy types 1 and 2. It also develops ORX142 for neurological and neurodegenerative disorders with symptoms such as daytime sleepiness and cognitive deficits, and ORX489 for neuropsychiatric disorders. LockBody directs effector activity into tumors. Founded 2020, based in Altrincham, UK.

Company score

Sentiment: 0.11; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.02; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.26; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.08; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive